Related Experiment Video
Updated: Jun 17, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy
I M Costa1, A I Serralheiro, M Rodrigues
1Pharmacology Department, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, Coimbra, Portugal.
Abstract:
Oral anticoagulation with warfarin is a widely used form of treatment for an increasing number of medical conditions. Nevertheless, appropriate therapeutic monitoring and dosage readjustments should be carried out in order to ensure its safety and efficacy. Although prothrombin time (usually expressed as International normalized ratio [INR]) is the most common warfarin response marker, clotting factors (namely factors II and X) are also indicated as alternative anticoagulant effect markers. In this paper, we examine the relationship between these warfarin response markers using information obtained from eighty 80 patients undergoing long-term warfarin therapy. Within the usual INR therapeutic range (2.0-3.5), a moderate inverse correlation between INR and both clotting factors II and X was observed. However, for INR values above 3.5, a non-proportional relationship were found between INR and both response markers. Therefore, it can be concluded that below critical clotting factor concentrations (20.6% and 15.6% of factors II and X activity, respectively), time required for clot formation becomes non-proportional and haemostasis will be jeopardised.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Therapeutic Index
Therapeutic Drug Monitoring: Affecting Factors
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
